KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Other financing activities (2016 - 2025)

LifeMD (LFMD) has disclosed Other financing activities for 10 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 126.73% year-over-year to $2.7 million, compared with a TTM value of $10.5 million through Dec 2025, up 1403.67%, and an annual FY2025 reading of $10.5 million, up 1403.67% over the prior year.
  • Other financing activities was $2.7 million for Q4 2025 at LifeMD, down from $3.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $4.5 million in Q1 2022 and bottomed at -$9.9 million in Q4 2024.
  • Average Other financing activities over 5 years is $2.3 million, with a median of $2.7 million recorded in 2023.
  • The sharpest move saw Other financing activities soared 2325.21% in 2021, then plummeted 372.52% in 2024.
  • Year by year, Other financing activities stood at $3.1 million in 2021, then plummeted by 39.42% to $1.9 million in 2022, then skyrocketed by 93.44% to $3.6 million in 2023, then tumbled by 372.52% to -$9.9 million in 2024, then skyrocketed by 126.73% to $2.7 million in 2025.
  • Business Quant data shows Other financing activities for LFMD at $2.7 million in Q4 2025, $3.2 million in Q3 2025, and $2.1 million in Q2 2025.